In life sciences, breakthroughs don’t happen overnight. They evolve from ideas in a lab notebook to commercial products that change lives. However, at every phase of that journey, risk evolves as well.
That’s why CCIG built a dedicated Life Sciences practice, and I’m proud to leverage my life sciences background alongside my insurance expertise to support our clients. It’s one thing to understand insurance. It’s another thing to understand how devices are designed, how research is funded, how clinical trials operate, and how products ultimately reach the market.
We call it our “Lab to IPO” philosophy: supporting companies from founding to commercialization, protecting today’s breakthroughs while preparing them for what comes next.
A start-up medical device company doesn’t look anything like a late-stage biotech. But traditional insurance often treats them the same. CCIG doesn’t.
Because our Life Sciences team is focused solely on this space, we understand the unique exposures associated with R&D, clinical trials, intellectual property, lab equipment, foreign operations, investor requirements, and the long timelines that characterize this industry.
This specialization enables us to do something most brokers can’t: tell a company’s story to carriers in the way underwriters need to hear it, because a well-told risk profile can mean broader coverage, better pricing, and fewer roadblocks as a company scales.
Life science organizations don’t fit into neat insurance categories. They’re too sophisticated for “basic insurance,” but too specialized for brokers who only dabble in the industry.
CCIG fills that gap.
Early-stage companies are naturally price-sensitive. Many are funded through grants, venture rounds, or even sweat equity.
We help them think strategically and optimize their budget:
When a company can show it’s been properly insured from the outset, it sends a powerful signal to future investors that you are built for growth and know how to manage risk.
As a company moves from R&D through clinical trials and into commercialization, its risk profile shifts dramatically. Most brokers only realize this once a problem appears. We build a strong risk management structure from the start.
Many trials take place outside the U.S., often because of speed, cost, or patient access. The challenge? Foreign governments usually require locally admitted insurance.
Because of our specialty carrier partnerships, we can seamlessly place those coverages. Clients avoid the hurdles of trying to procure insurance directly through foreign carriers, especially in highly regulated countries.
When products move from research to human use, exposures evolve:
The line between product error and professional negligence can blur fast. We craft combined liability solutions that protect both sides of the risk before a claim ever happens.
For life sciences, IP is the business. We help protect:
When science moves fast, risk follows. You deserve a partner who understands both.
CCIG’s Life Sciences division protects companies from the lab bench to IPO, with a team that understands the industry, its exposures, and the carriers that specialize in this field.
We act as translators between innovators and underwriters to help companies grow with confidence, compliance, and the right protections in place at every milestone.
If you’d like to discuss your insurance strategy, please reach out for a conversation.
Back to Resources